Skip to main content
Top
Published in: Abdominal Radiology 7/2019

01-07-2019 | Hepatocellular Carcinoma | Classics in Abdominal Radiology

“Nodule-in-nodule” architecture of hepatocellular carcinoma

Authors: Dario Giambelluca, Roberto Cannella, Giovanni Caruana, Giuseppe Brancatelli

Published in: Abdominal Radiology | Issue 7/2019

Login to get access

Excerpt

The “nodule-in-nodule” architecture of hepatocellular carcinoma (HCC) is defined by the presence of one or more smaller inner nodules having different imaging features than a larger outer nodule (Fig. 1) [1]. This appearance is a variant of the “mosaic” architecture of HCC, that is defined as the presence of randomly distributed internal nodules or compartments, with different imaging features regarding enhancement, attenuation, intensity, and size [1, 2].
Literature
Metadata
Title
“Nodule-in-nodule” architecture of hepatocellular carcinoma
Authors
Dario Giambelluca
Roberto Cannella
Giovanni Caruana
Giuseppe Brancatelli
Publication date
01-07-2019
Publisher
Springer US
Published in
Abdominal Radiology / Issue 7/2019
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-019-02001-7

Other articles of this Issue 7/2019

Abdominal Radiology 7/2019 Go to the issue

Classics in Abdominal Radiology

Thimble bladder

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine